Robin Fischer, APRN
Family · Niceville, FLNPI 1689037327
Payments from drug & device makers
Across 360 payments — averaging $79.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$17K
- Inspire Medical Systems, Inc.$4K
- ZOLL Respicardia, Inc.$1K
- Medtronic$1K
- Jazz Pharmaceuticals Inc.$501
- Novo Nordisk$406
- plus $4K from 32 others
What the payments were for
- Consulting fees$2,4008%
- Speaking & faculty fees$10,80038%
- Travel & lodging$6,28622%
- Food & beverage$8,89131%
- Education$890%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 64 | $16,982 |
| Inspire Medical Systems, Inc. | 107 | $4,021 |
| ZOLL Respicardia, Inc. | 4 | $1,367 |
| Medtronic | 16 | $1,259 |
| Jazz Pharmaceuticals Inc. | 14 | $501 |
| Novo Nordisk | 21 | $406 |
| AstraZeneca | 10 | $388 |
| Boston Scientific | 4 | $357 |
| Bayer | 8 | $297 |
| E.r. Squibb & Sons, L.L.C. | 5 | $241 |
| Amgen | 9 | $238 |
| United Therapeutics Corporation | 4 | $232 |
| AbbVie | 7 | $230 |
| Axsome Therapeutics, Inc. | 6 | $216 |
| Merck | 10 | $162 |
| Johnson & Johnson | 8 | $155 |
| Harmony Biosciences LLC | 6 | $127 |
| Cvrx, Inc. | 1 | $125 |
| Regeneron Healthcare Solutions, Inc. | 1 | $125 |
| GSK | 8 | $119 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $118 |
| Avadel CNS Pharmaceuticals, LLC | 3 | $110 |
| Novartis | 4 | $83 |
| Kestra Medical Technology Services, Inc. | 3 | $65 |
| Gilead | 4 | $62 |
| Kowa Pharmaceuticals America, Inc. | 4 | $60 |
| Baxter Healthcare | 1 | $55 |
| Pfizer | 3 | $54 |
| Boehringer Ingelheim | 3 | $49 |
| Biohaven Pharmaceuticals, Inc. | 3 | $46 |
| Eisai Inc. | 3 | $45 |
| Amarin Pharma, Inc. | 2 | $44 |
| Sanofi-aventis U.S. LLC | 3 | $39 |
| Philips North America LLC | 1 | $25 |
| Preventice Services, LLC | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Global Blood Therapeutics, Inc. | 1 | $16 |
| Currax Pharmaceuticals LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZEPBOUND$11,295
- Inspire$1,719
- remede System$1,295
- VenaSeal$801
- WATCHMAN FLX$294
- Barostim Neo System$125
- Kerendia$125
- TEZSPIRE$125
- VRAYLAR$125
- DUPIXENT$125
- CAMZYOS$122
- Repatha$122
- BREZTRI$121
- SUNOSI$110
How this compares
$28,466 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| WakixPitolisant Hcl | 12 | $182,621 |
| EliquisApixaban | 149 | $165,450 |
| EntrestoSacubitril/Valsartan | 128 | $143,252 |
| JardianceEmpagliflozin | 66 | $77,395 |
| XareltoRivaroxaban | 57 | $71,078 |
| Repatha SyringeEvolocumab | 25 | $23,514 |
| FarxigaDapagliflozin Propanediol | 15 | $19,710 |
| Repatha SureclickEvolocumab | 23 | $19,361 |
| OzempicSemaglutide | 14 | $11,203 |
| Metoprolol Succinate | 211 | $2,702 |
| Clonidine | 17 | $2,403 |
| Rosuvastatin Calcium | 158 | $2,243 |
| Chlorthalidone | 102 | $1,998 |
| Atorvastatin Calcium | 187 | $1,761 |
| Losartan Potassium | 148 | $1,740 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Harmony Biosciences LLCWakix | $127 | $182,62112 claims |
| PfizerEliquis | $54 | $165,450149 claims |
| NovartisEntresto | $83 | $143,252128 claims |
| Boehringer IngelheimJardiance | $49 | $77,39566 claims |
| Johnson & JohnsonXarelto | $155 | $71,07857 claims |
| AstraZenecaFarxiga | $388 | $19,71015 claims |
| Novo NordiskOzempic | $406 | $11,20314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in Niceville
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.